UCPMP 2024 Explained: The Compliance Guide for Pharma Marketing Teams

What is UCPMP 2024?

UCPMP 2024 stands for the Uniform Code for Pharmaceutical Marketing Practices, 2024. The Department of Pharmaceuticals (DoP), under India's Ministry of Chemicals and Fertilizers, issued it in March 2024 to replace the 2015 code.

The code sets the ethical standard for how pharmaceutical and medical device companies market their products. It touches almost every promotional activity a commercial team runs, including:

• Gifts, cash and benefits to healthcare professionals (HCPs)
• Free drug samples
• Travel, hospitality and event sponsorship
• Continuing Medical Education (CME) and Continuing Professional Development (CPD)
• Promotional and educational materials, both print and digital
• The conduct of medical representatives

In simple terms: if your brand talks to a doctor, this pharma marketing code has something to say about how you do it.

Who must follow the code?

The rules apply to every pharmaceutical company, every medical device company, and their agents — including marketing agencies, distributors, and any third party acting on the company's behalf. If you outsource a campaign, the responsibility still sits with you.

Is UCPMP 2024 mandatory or voluntary?

This is the first question every marketing head asks, so let's answer it directly.

The code is technically self-regulatory, not a statutory law — but treating it as "optional" is a serious mistake. The government deliberately deleted the word "voluntary" that appeared in the 2015 version. UCPMP 2024 is enforced through pharmaceutical associations, and it now carries powers that did not exist before.

Here is what changed in practice:

• The DoP can order an audit of any company after a complaint.
• If a breach is proven, the DoP can recommend action to other agencies, such as the Income Tax Department and the National Pharmaceutical Pricing Authority (NPPA).
• An appellate committee, headed by the Secretary of the DoP, can prescribe penalties.
• Your CEO must file an annual self-declaration of compliance.

So while the code is not a criminal statute, the financial and reputational consequences are real. Smart companies treat it as mandatory.

UCPMP 2024 vs 2015: what actually changed

The new version is stricter, clearer, and far harder to ignore. The table below compares the two codes on the points that matter most to marketers.

Takeaway: the 2024 version closes the loopholes that made the older code easy to sidestep.

What the code allows and bans: a quick reference

Use this table as a fast desk reference before approving any campaign or rep activity.

The key UCPMP 2024 rules, explained

Now let's break down each major rule so your team knows exactly where the line sits.

1. Gifts and freebies are banned

Pharma companies and their agents cannot give any gift, cash, monetary benefit, or pecuniary advantage to a healthcare professional or their family. This includes the classic perks the industry once relied on — electronics, vouchers, expensive dinners, and personal travel.

The intent is simple: a prescription should be based on science, not on who gave the nicest gift.

2. Brand reminders have a ₹1,000 ceiling

You can still leave educational and informational items, but the rules are tight. Permitted items include books, print and electronic journals, calendars, diaries, dummy device models, and clinical treatment guidelines.

Two conditions apply to every item:

• The value must not exceed ₹1,000 per item.
• The item must have no independent commercial value to the doctor — they should not be able to resell it.
  3. Free samples are capped two ways
• Samples remain legal because they help doctors evaluate a product. But the code now sets firm numerical limits:
• A maximum of 12 sample packs per drug, per healthcare professional, per year.
• The total value of all samples must not exceed 2% of the company's domestic sales per year.
• Samples may only go to HCPs qualified to prescribe that product.
• Each sample must be marked "free sample — not for sale."
• You must keep records: the HCP's name, the product, the quantity, and the date.
• This is where many companies will struggle, because most do not track sample distribution at this level of detail today.
• 4. Travel, hospitality and CME are heavily restricted
• Paid travel, hotels, and hospitality for doctors are not allowed. The only meaningful exception is for CME or CPD speakers — a company may cover travel and hospitality for an invited speaker, but not for delegates or attendees.
• CME and CPD programs themselves must follow transparent, well-documented guidelines, and companies must keep a database of every event they support.
• 5. Promotional claims must be honest
• Every claim you make about a drug must be accurate, balanced, up to date, and substantiated by evidence. The code adds specific guardrails:
• The word "new" can only describe a drug that has been in India for less than one year.
• The word "safe" should never be used without proper qualification.
• Comparative and superlative claims ("the best," "the most effective") need solid evidence.
• 6. Medical representatives must maintain standards
• Your field force represents the brand. Under the code, medical representatives must not use any inducement to gain access to doctors, must present information honestly, and must follow the same ethical standards as the rest of the company.

5 common UCPMP 2024 compliance mistakes (and how to avoid them)

Most breaches are not deliberate. They come from old habits and weak record-keeping. Here are the five mistakes we see most often.

1. Treating the code as voluntary. The word "voluntary" is gone. Build your processes as if an audit could come tomorrow.
2. No sample register. Distributing samples without tracking the 12-pack and 2% limits is the most common gap. Log every sample at the point of handover.
3. Expensive "brand reminders." Branded electronics, premium bags, or anything resellable now breaks the ₹1,000, no-commercial-value rule.
4. Sponsoring delegate travel. Paying for a doctor to attend a conference as a delegate is not allowed — only invited speakers qualify.
5. Ignoring data consent. A campaign can be perfectly ethical under the marketing code and still illegal under the DPDP Act if you message a doctor without consent. Check both.

Fix these five, and you remove the large majority of your real-world risk.

Real-world UCPMP 2024 scenarios

Rules are easier to follow with examples. Here is how the code applies to everyday decisions a brand team faces.

Keep this table handy for fast approvals.

UCPMP 2024 penalties: what happens if you break the code

Because the code runs through industry associations, penalties are administrative and reputational rather than criminal. But for a listed or growth-stage pharma company, the impact can be severe.

Possible consequences include:

1. Reprimand and corrective action from the ethics committee.
2. Recovery of the money or item involved in the violation.
3. Public naming — the details of the breach can be published.
4. Suspension or expulsion from the pharmaceutical association.
5. Referral to other agencies — the DoP can recommend action by the Income Tax Department or NPPA.The reputational hit — being publicly named for unethical marketing — often costs more than any fine.

Who enforces the pharma marketing code?

Enforcement runs through a layered structure. Knowing who sits where helps you respond correctly if a complaint is ever filed.

• Pharmaceutical associations (such as IPA and OPPI) host an Ethics Committee for Pharmaceutical Marketing Practices (ECPMP) that receives and reviews complaints.
• The Department of Pharmaceuticals (DoP) can order an audit when a complaint is raised, and can escalate proven breaches.
• An appellate committee, headed by the Secretary of the DoP, hears appeals and can prescribe penalties.

Complaints can come from competitors, doctors, or whistle-blowers — which means compliance is not just an internal checkbox, it is a competitive risk.

UCPMP vs DPDP Act: two codes, one compliant strategy

Here is the part most guides miss. Indian pharma marketing now sits under two rulebooks at the same time, and they cover different things.

• UCPMP 2024 governs your marketing *conduct* — gifts, claims, samples, and hospitality.
• The DPDP Act 2023 governs your handling of *personal data* — doctor and patient information, consent, and privacy.

You can run a perfectly ethical campaign under the marketing code and still break the DPDP Act if you message a doctor without valid consent. The reverse is also true. Compliant pharma marketing in India means clearing both at once.

Bottom line: build one compliance workflow that satisfies both codes, instead of two disconnected efforts.

Why the code matters for growth-stage and listed pharma

For founders and CXOs, compliance is no longer just a legal box to tick — it is a trust and valuation issue.

• Investor and IPO readiness. Diligence teams now check marketing-compliance frameworks. A clean record removes a red flag before it appears.
• ESG and governance. Ethical promotion sits squarely inside the "G" of ESG, which institutional investors increasingly score.
• Brand trust with doctors. Physicians respect companies that engage on science, not incentives. Compliance becomes a differentiator, not a cost.

In a market moving toward transparency, the companies that operationalise UCPMP 2024 early will look the most credible to investors, regulators, and HCPs alike.

UCPMP 2024 compliance checklist for marketing teams

Use this checklist to move from "aware of the code" to "audit-ready." Tick each item.

1. Appoint an owner. Name one person accountable for marketing-code compliance.
2. Publish your code. Put your marketing-practices framework on your company website.
3. File the CEO declaration. Ensure your executive head signs the annual compliance undertaking on time.
4. Build a sample register. Track every sample by HCP name, product, quantity, and date — and enforce the 12-pack and 2% limits.
5. Audit your giveaways. Remove anything above ₹1,000 or with resale value from your brand-reminder kit.
6. Review every claim. Check that "new," "safe," and comparative claims are evidence-backed.
7. Control CME spend. Document programs and limit travel and hospitality to speakers only.
8. Train your field force. Run training for reps and managers, and keep attendance records.
9. Log your events. Maintain a database of all CME and CPD activities you support.
10. Map data consent (DPDP). Confirm you have valid consent before contacting any doctor digitally.

Print this list, assign owners, and review it every quarter.

How to operationalize compliance (without slowing the team down)

Most breaches happen because records, approvals, and consent trails live in scattered spreadsheets and inboxes. The fix is to make compliance part of the workflow, not a separate burden.

Three practical moves help:

• Centralize HCP data and consent. Keep one clean, validated record per doctor, with consent status and contact history attached. This serves both the marketing code's record-keeping and the DPDP Act's consent rules.
• Automate sample and event tracking. Replace manual logs with a system that flags when a doctor nears the 12-pack limit or the 2% value cap.
• Add a compliance check to content approval. Screen promotional claims and brand reminders before they reach a rep or a screen.

This is exactly where a compliant, India-ready marketing platform earns its keep. Multiplier AI's DPDP-compliant HCP marketing helps pharma teams keep clean doctor data, capture and honour consent, and run omnichannel campaigns with the audit trails that both UCPMP 2024 and the DPDP Act expect.

Frequently Asked Questions For UCPMP 2024